Alnylam Pharma (ALNY) Tops Q3 EPS by 15c, Misses on Revenue, Offers FY22 Revenue Guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $266.11 --0%
Revenue Growth %: +15.3%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
CAN, UNFI, SUNB, More
Revenue Growth %: +15.3%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
CAN, UNFI, SUNB, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q3 EPS of ($1.58), $0.15 better than the analyst estimate of ($1.73). Revenue for the quarter came in at $264.3 million versus the consensus estimate of $293.08 million.
GUIDANCE:
Alnylam Pharma sees FY2022 revenue of $870-930 million, versus the consensus of $1.02 Billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- TD Cowen Reiterates Hold Rating on Leidos Holdings (LDOS)
- Roth/MKM Downgrades eGain Corporation (EGAN) to Neutral
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
